Skip to main content
Erschienen in: Journal of General Internal Medicine 1/2020

28.10.2019

Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling

verfasst von: Bansri Desai, PharmD, Kyungwan Hong, PharmD, MS, John H. Powers III, MD, Peter Doshi, PhD

Erschienen in: Journal of General Internal Medicine | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Obtaining an accurate understanding of the known benefits and risks of drugs is difficult, particularly when drugs first come to market. The most robust evidence is largely limited to pre-marketing studies (e.g., phase 3 trials), but the peer-reviewed literature describing these studies may be incomplete (e.g., with unpublished trials), and systematic reviews often have yet to be conducted. Despite their reputation as unhelpful, FDA-approved prescribing information (also known as “package inserts” or “drug labels”) should provide clinicians with a trustworthy source of information about new drugs that has been independently vetted. …
Literatur
Metadaten
Titel
Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling
verfasst von
Bansri Desai, PharmD
Kyungwan Hong, PharmD, MS
John H. Powers III, MD
Peter Doshi, PhD
Publikationsdatum
28.10.2019
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 1/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05460-2

Weitere Artikel der Ausgabe 1/2020

Journal of General Internal Medicine 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.